HomePLX • NYSEAMERICAN
add
Protalix Biotherapeutics Inc
Previous close
$1.83
Day range
$1.80 - $1.85
Year range
$1.32 - $3.10
Market cap
147.17M USD
Avg Volume
810.16K
P/E ratio
106.87
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 17.85M | -0.60% |
Operating expense | 7.40M | 32.24% |
Net income | 2.36M | -27.22% |
Net profit margin | 13.19 | -26.80% |
Earnings per share | — | — |
EBITDA | 2.50M | -42.06% |
Effective tax rate | -5.18% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 29.37M | 7.15% |
Total assets | 82.26M | 33.63% |
Total liabilities | 29.36M | 0.79% |
Total equity | 52.91M | — |
Shares outstanding | 80.42M | — |
Price to book | 2.77 | — |
Return on assets | 6.63% | — |
Return on capital | 9.16% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | 2.36M | -27.22% |
Cash from operations | -3.73M | -190.91% |
Cash from investing | -504.00K | -102.48% |
Cash from financing | 0.00 | 100.00% |
Net change in cash | -4.25M | -205.94% |
Free cash flow | -6.02M | -671.68% |
About
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease. Wikipedia
CEO
Founded
1993
Headquarters
Website
Employees
213
